文献速递前列腺癌

短期达罗他胺(ODM-201)联合放疗治疗不利型中危前列腺癌患者:DARIUS(AFU-GETUG P15)2期试验方案

Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol.
PubMed 文献 · Eur Urol Oncol · 2024-05-16

DARIUS是一项多中心随机非比较性2期试验,纳入62例不利型中危前列腺癌患者,随机接受6个月达罗他胺+外照射放疗或6个月雄激素剥夺治疗(ADT)+外照射放疗。主要终点为第6个月前列腺特异性抗原≤0.1 ng/ml的生物学缓解,关键次要终点包括生化复发无生存、无病生存、安全性和生活质量。作者认为达罗他胺+外照射放疗可能在生物学缓解方面有效,同时避免ADT相关毒性和生活质量改变。

要点

  • DARIUS试验评估6个月达罗他胺联合外照射放疗对比6个月ADT联合外照射放疗。
  • 主要终点为第6个月前列腺特异性抗原≤0.1 ng/ml的生物学缓解。
  • 计划纳入62例不利型中危前列腺癌患者,随机非比较设计。

核心结论

  • 6个月达罗他胺+外照射放疗对比6个月ADT+外照射放疗,可能在不力型中危前列腺癌患者中实现生物学缓解,同时避免ADT相关毒性和生活质量改变。

研究设计与样本

  • DARIUS试验为多中心随机非比较性2期试验,计划纳入62例不利型中危前列腺癌患者,随机分配至6个月达罗他胺+外照射放疗组或6个月ADT+外照射放疗组。

主要发现

  • 主要终点为达罗他胺或ADT第6个月时前列腺特异性抗原≤0.1 ng/ml的生物学缓解。
  • 关键次要终点包括生化复发无生存、无病生存、安全性和生活质量。
  • 计划开展影像组学和基因组分类器的辅助研究。

临床怎么用

  • 作者认为,在需要ADT联合外照射放疗的患者中,单用达罗他胺等雄激素受体靶向药物可能显示抗肿瘤疗效,同时减少毒性并维持生活质量。

局限性

  • 局限性主要在于本研究的开放标签设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination of androgen deprivation therapy (ADT) with external beam radiation therapy (EBRT) is a standard of care for patients with intermediate-risk prostate cancer (PCa). However, 6 months of ADT generates multiple side effects impacting quality of life (QoL). Darolutamide (an androgen receptor targeting agent [ARTA]) is associated with low blood-brain barrier penetrance and less drug-drug interaction. OBJECTIVE: To assess the efficacy of a combination of 6 months of darolutamide with EBRT to treat patients with unfavorable intermediate-risk PCa. DESIGN, SETTING, AND PARTICIPANTS: The DARIUS trial is a multicenter randomized non comparative phase 2 trial, randomizing the 6-months darolutamide + EBRT arm versus 6-months ADT + EBRT in patients with unfavorable intermediate-risk PCa. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint is a biological response defined as prostate-specific antigen ≤0.1 ng/ml at month six of darolutamide or ADT. The key secondary endpoints are biochemical recurrence-free survival, disease-free survival, safety, and QoL. Ancillary studies using radiomics and genomic classifier are planned. Sixty-two patients will be included. RESULTS AND LIMITATIONS: In this population of patients requiring ADT combined with EBRT, the use of an ARTA alone, such as darolutamide, may demonstrate antitumoral efficacy while minimizing toxicity and maintaining QoL. Limitations are mainly inherent to the open-label design of this study. CONCLUSIONS: Six months of darolutamide + EBRT compared with 6 months of ADT + EBRT may be efficient in terms of a biological response, avoiding toxicity and altered QoL attributable to ADT in patients with unfavorable intermediate-risk PCa. PATIENT SUMMARY: The ongoing DARIUS clinical trial assesses short-term (6 months) darolutamide treatment in association with external beam radiation therapy in men with localized prostate cancer. The trial investigates whether single-agent darolutamide can improve the biological response while maintaining a favorable tolerability profile.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sargos P, Bellera C, Bentahila R, et al. Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol. Eur Urol Oncol. 2024. PMID: 38755095. doi:10.1016/j.euo.2024.04.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。